Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRX 1 - Tolerx

Drug Profile

TRX 1 - Tolerx

Alternative Names: Anti-CD4 monoclonal antibody - Tolerx; MTRX 1011A; RG 7424; TRX1 - Tolerx

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Oxford
  • Developer Genentech; Tolerx
  • Class Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; CD45 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Cutaneous lupus erythematosus; Rheumatoid arthritis

Most Recent Events

  • 07 Oct 2011 Discontinued - Phase-I for Autoimmune disorders in United Kingdom (Parenteral)
  • 07 Oct 2011 Discontinued - Phase-I for Cutaneous lupus erythematosus in USA (Parenteral)
  • 05 Aug 2008 Genentech initiates enrolment in a phase I trial of MTRX1011A (a modified version of TRX 1) in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top